Recursion Pharmaceuticals Inc Revenue Growth Rates (RXRX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Recursion Pharmaceuticals Inc   (NASDAQ: RXRX)
 

RXRX's Revenue Growth by Quarter and Year

Recursion Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/RXRX/growth
https://api.csimarket.com/api/v1/companies/RXRX/fundamentals
https://api.csimarket.com/api/v1/companies/RXRX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
RXRX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 18.55
2nd Quarter June 7.67
1st Quarter March 6.47
FY 32.69

RXRXs Annual Revenue
Recursion Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 74.68 millions
Recursion Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 58.84 millions
Recursion Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 44.58 millions
Recursion Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 39.84 millions
Recursion Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 10.18 millions




RXRX Revenue third quarter 2026 Y/Y Growth Comment
Recursion Pharmaceuticals Inc achieved in the third quarter 2026, above Company average Revenue surge of 258.15% year on year, to $ 18.55 millions.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 32 other companies have achieved higher Revenue growth. While Recursion Pharmaceuticals Inc ' s Revenue doubling of 258.15% ranks overall at the positon no. 1720 in the third quarter 2026.


RXRX Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 258.15 %
2nd Quarter June -60.09 %
1st Quarter March -56.14 %
FY   -

Financial Statements
Recursion Pharmaceuticals Inc 's third quarter 2026 Revenue $ 18.55 millions RXRX's Income Statement
Recursion Pharmaceuticals Inc 's third quarter 2025 Revenue $ 5.18 millions Quarterly RXRX's Income Statement


RXRX Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 141.88 %
2nd Quarter June 18.55 %
1st Quarter March -81.8 %
FY (Year on Year)   -


Back to RXRX Growth rate Comparisons >> Back to RXRX Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #33
Healthcare Sector #274
Overall #1720

Revenue Y/Y Growth Statistics
High Average Low
291.46 % 76.96 % -32.98 %
(Dec 31 2022)   (Sep 30 2025)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #33
Healthcare Sector #274
Overall #1720
Revenue Y/Y Growth Statistics
High Average Low
291.46 % 76.96 % -32.98 %
(Dec 31 2022)   (Sep 30 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Recursion Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
586.72 % 70.43 % -82.57 %
(Dec 31 2025)  


RXRX's III. Quarter Q/Q Revenue Comment
Recursion Pharmaceuticals Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 141.88%, to $ 18.55 millions, from $7.67 millions in the second quarter.
RXRX is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Biotechnology & Pharmaceuticals industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Recursion Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 533.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #15
Healthcare Sector #101
Overall #533
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #15
Healthcare Sector #101
Overall #533
Revenue Q/Q Growth Statistics
High Average Low
586.72 % 70.43 % -82.57 %
(Dec 31 2025)  


RXRX's III. Quarter Q/Q Revenue Comment
Recursion Pharmaceuticals Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 141.88%, to $ 18.55 millions, from $7.67 millions in the second quarter.
RXRX is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Biotechnology & Pharmaceuticals industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Recursion Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 533.


Recursion Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 68.23
Y / Y Revenue Growth (TTM) 56.18 %
Year on Year Revenue Growth Overall Ranking # 559
Seqeuential Revenue Change (TTM) 24.39 %
Seq. Revenue Growth (TTM) Overall Ranking # 1720


Cumulative Revenue growth Comment
Although Recursion Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 76.96% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 56.18% year on year, from -15.08% in Jun 30 2026.

In the Healthcare sector 126 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 249 to 559.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 33
Healthcare Sector # 127
Overall # 559

Revenue TTM Y/Y Growth Statistics
High Average Low
291.46 %
 76.96 %
-32.98 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 33
Sector # 274
S&P 500 # 1720
Cumulative Revenue growth Comment
Although Recursion Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 76.96% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 56.18% year on year, from -15.08% in Jun 30 2026.

In the Healthcare sector 126 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 249 to 559.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 33
Healthcare Sector # 127
Overall # 559

Revenue TTM Y/Y Growth Statistics
High Average Low
291.46 %
76.96 %
-32.98 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 33
Sector # 274
S&P 500 # 1720




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RXRX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Tonix Pharmaceuticals Holding Corp 423.83%$ 423.830 millions
Nakamoto Inc 396.90%$ 396.897 millions
EBR Systems, Inc.385.65%$ 385.647 millions
Solana Company382.07%$ 382.066 millions
Pulse Biosciences Inc 359.30%$ 359.302 millions
Ensysce Biosciences Inc 342.43%$ 342.428 millions
Nexalin Technology Inc 331.43%$ 331.434 millions
Agios Pharmaceuticals Inc 330.01%$ 330.008 millions
Insmed Inc330.00%$ 330.000 millions
Monte Rosa Therapeutics Inc 325.80%$ 325.799 millions
Liquidia Corporation314.60%$ 314.596 millions
Stablecoin Development Corporation310.75%$ 310.749 millions
Renovorx Inc 300.75%$ 300.752 millions
Aligos Therapeutics Inc 281.92%$ 281.916 millions
Clene Inc 273.33%$ 273.333 millions
Recursion Pharmaceuticals Inc 258.49%$ 258.493 millions
Nuvation Bio Inc 251.98%$ 251.977 millions
Seastar Medical Holding Corp246.99%$ 246.995 millions
Prime Medicine Inc 243.92%$ 243.918 millions
Urogen Pharma Ltd 227.16%$ 227.161 millions
Dianthus Therapeutics Inc 205.56%$ 205.556 millions
Bridgebio Pharma Inc 192.60%$ 192.602 millions
Bicycle Therapeutics Plc190.24%$ 190.242 millions
Gossamer Bio Inc 189.09%$ 189.085 millions
Alpha Cognition Inc.173.75%$ 173.751 millions
Eton Pharmaceuticals Inc 165.04%$ 165.042 millions
Sera Prognostics Inc 162.50%$ 162.500 millions
Volitionrx Limited157.28%$ 157.283 millions
Neuraxis Inc 149.92%$ 149.922 millions
Pluri Inc 140.19%$ 140.190 millions


About Recursion Pharmaceuticals Inc Revenue Growth Rates (RXRX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Recursion Pharmaceuticals Inc (CIK 1601830).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001601830-26-000145
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Recursion Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.